NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF, bosentan, pulmonary arterial hypertension, and others. The company markets its products in approximately 40 countries, including India, the United States, and internationally.NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. The ISIN of this stock is INE987B01026.